Sanofi's US NDA for Victoza rival accepted for review
This article was originally published in Scrip
Executive Summary
The US FDA has accepted for review a new drug application (NDA) for Sanofi/Zealand Pharma's lixisenatide, a once-daily prandial GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. The news follows the EU approval of lixisenatide on 1 February 2013, where it has the brand name Lyxumia (scripintelligence.com, 4 February 2013).